Shared Decision Making in Hemophilia Patient Care Grant

Shared Decision Making in Hemophilia Patient Care Grant

Status: ACTIVE
Funder: Pfizer, Inc.
Amount: Up to US $30,000
Last Updated: June 11, 2025

Summary

The Shared Decision Making in Hemophilia Patient Care grant program, funded by Pfizer, aims to enhance patient outcomes through Quality Improvement projects that integrate shared decision-making tools into hemophilia care. This initiative encourages multidisciplinary collaboration to address healthcare disparities and empower patients in their disease management. Eligible organizations include healthcare institutions and professional schools, fostering innovative approaches to improve care for individuals living with hemophilia.

Overview

Competitive Grants Program Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Shared Decision Making in Hemophilia Patient Care Shared Decision Making (SDM) plays a vital role in the interaction between individuals living with hemophilia (PlwH), their caregivers, and the multidisciplinary teams at hemophilia treatment centers. This competitive grant program aims to support Quality Improvement (QI) projects that integrate SDM tools and care algorithms into hemophilia patient care. Project Types and Area of Interest It is our intent to support projects focusing on Implementing shared decision making (SDM) tools and/or management of care algorithms into hemophilia patient care. Multi-disciplinary collaborations are encouraged when appropriate, but all partners must have a relevant role.Identifying significant barriers that contribute to geographic, gender and racial healthcare disparities disproportionatelyimpacting the Hemophilia community. The goal is to enhance early detection and determine targeted interventions that address these challenges with focus on SDM.Exploring empowering strategies that enable patients to actively participate in their care, as well as in making informed decisions regarding disease management options.

Eligibility

You can learn more about this opportunity by visiting the funder's website. The following may apply: medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional organizations; government agencies; and other entities with a mission related to healthcare improvement.Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society).The applicant must be the Project Lead/Principal Investigator (PI) or an authorized designee of such individual (e.g., Project Lead/PI’s grant/research coordinator).The Project Lead/PI must be an employee or contractor of the requesting organization. Requesting organization must be legally able to receive award funding directly from Pfizer Inc. We strongly recommend that applicants confirm this with their organization or institution prior to submitting an application.

Ineligibility

It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Pfizer Inc. may be subject to rescission.